Bosutinib price

Bosutinib (Bosutinib) is a drug used to treat chronic myeloid leukemia (CML) and belongs to a class of tyrosine kinase inhibitors. CML is a type of leukemia caused by genetic mutations in bone marrow cells. Abnormalities in the BCR-ABL fusion gene produce abnormal tyrosine kinases, leading to abnormal cell proliferation.

Bosutinib is not currently available in the country, so patients cannot purchase it domestically and need to buy it through overseas channels. There are original drugs and generic drugs of bosutinib abroad. The original drugs include the Turkish original drug and the European version of the original drug. The Turkish version of the original drug costs about 2,000 to 3,000 yuan, and the European version of the original drug costs about 30,000 yuan. In addition, there are cheaper generic drugs, which cost more than one thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

Bosutinib works by inhibiting the activity of this abnormal kinase, thereby slowing or stopping the growth and division of leukemia cells. Compared with other tyrosine kinase inhibitors, bosutinib has certain advantages in selectivity and can more accurately interfere with the activity of abnormal kinases and reduce adverse effects on normal cells.

This drug is often used to treat patients with chronic myelogenous leukemia, especially those who are resistant to or intolerant of other treatments. The use of bosutinib can help control the development of leukemia and improve patients' survival rate and quality of life.

However, bosutinib may also cause some side effects, including digestive problems such as nausea, vomiting, and diarrhea, as well as systemic symptoms such as fatigue and joint pain. During use, doctors usually monitor the patient's blood indicators and other physiological parameters to ensure the safety and effectiveness of the drug.